EP3148538A4 - Cenicriviroc for the treatment of hiv-2 infection - Google Patents

Cenicriviroc for the treatment of hiv-2 infection Download PDF

Info

Publication number
EP3148538A4
EP3148538A4 EP15802519.7A EP15802519A EP3148538A4 EP 3148538 A4 EP3148538 A4 EP 3148538A4 EP 15802519 A EP15802519 A EP 15802519A EP 3148538 A4 EP3148538 A4 EP 3148538A4
Authority
EP
European Patent Office
Prior art keywords
cenicriviroc
hiv
infection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15802519.7A
Other languages
German (de)
French (fr)
Other versions
EP3148538A1 (en
Inventor
Eric Lefebvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobira Therapeutics Inc
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of EP3148538A1 publication Critical patent/EP3148538A1/en
Publication of EP3148538A4 publication Critical patent/EP3148538A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP15802519.7A 2014-06-02 2015-06-02 Cenicriviroc for the treatment of hiv-2 infection Withdrawn EP3148538A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462006492P 2014-06-02 2014-06-02
PCT/US2015/033737 WO2015187663A1 (en) 2014-06-02 2015-06-02 Cenicriviroc for the treatment of hiv-2 infection

Publications (2)

Publication Number Publication Date
EP3148538A1 EP3148538A1 (en) 2017-04-05
EP3148538A4 true EP3148538A4 (en) 2018-01-17

Family

ID=54767270

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15802519.7A Withdrawn EP3148538A4 (en) 2014-06-02 2015-06-02 Cenicriviroc for the treatment of hiv-2 infection

Country Status (4)

Country Link
US (1) US20170105969A1 (en)
EP (1) EP3148538A4 (en)
MA (1) MA39991A (en)
WO (1) WO2015187663A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045043A1 (en) 2016-08-31 2018-03-08 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232028A1 (en) * 2001-08-08 2012-09-13 Tobira Therapeutics, Inc. Bicyclic Compound, Production and Use Thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291631B2 (en) * 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
CN101941964A (en) * 2003-04-22 2011-01-12 阿诺麦德股份有限公司 Has the Chemokine Receptors bonded heterogeneous ring compound that promotes effect
EP2285807A1 (en) * 2008-05-09 2011-02-23 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232028A1 (en) * 2001-08-08 2012-09-13 Tobira Therapeutics, Inc. Bicyclic Compound, Production and Use Thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. VISSEAUX ET AL: "In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 56, no. 1, 1 January 2012 (2012-01-01), pages 137 - 139, XP055433798, ISSN: 0066-4804, DOI: 10.1128/AAC.05313-11 *
BENOIT VISSEAUX ET AL: "Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates", PLOS ONE, vol. 10, no. 8, 6 August 2015 (2015-08-06), pages e0134904, XP055431315, DOI: 10.1371/journal.pone.0134904 *
See also references of WO2015187663A1 *

Also Published As

Publication number Publication date
WO2015187663A1 (en) 2015-12-10
MA39991A (en) 2015-12-10
US20170105969A1 (en) 2017-04-20
EP3148538A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
EP3388004A4 (en) Treatment instrument
EP3160405A4 (en) Treatment of the ear
EP3102225A4 (en) Combination therapy for treatment of hbv infections
EP3119401A4 (en) Cenicriviroc for the treatment of fibrosis
EP3153104A4 (en) Medical treatment system
EP3179993A4 (en) Method for the treatment of depression
EP3157565A4 (en) Treatment of polybacterials infections
EP3238761A4 (en) Blood treatment system
EP3374502A4 (en) Methods for the treatment of corneal dystrophies
EP3183240A4 (en) Treatment of joint conditions
EP3227276A4 (en) Combinations for the treatment of neuroblastoma
EP3362091A4 (en) Combination treatment
EP3269316A4 (en) Treatment instrument
EP3106097A4 (en) Treatment instrument
HK1257272A1 (en) Means for the treatment of hiv
EP3405183A4 (en) Adamatane derivatives for the treatment of filovirus infection
EP3122349A4 (en) Compositions for the treatment of autodigestion
EP3099304A4 (en) Novel therapeutics for the treatment of glaucoma
EP3200749A4 (en) Methods for the treatment of peri-implantitis
EP3095378A4 (en) Medical treatment system
EP3106112A4 (en) Treatment instrument
EP3275495A4 (en) Treatment instrument
EP3106119A4 (en) Treatment instrument
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
EP3183270A4 (en) Hiv antibody therapy as treatment substitute

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20171220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20171214BHEP

Ipc: A61K 31/4178 20060101AFI20171214BHEP

Ipc: A61K 31/4748 20060101ALI20171214BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180719